• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

    67.88 +0.76 (+1.13%)
    Streaming Delayed Price Updated: 10:50 AM EDT, May 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 367,759
    Open 68.03
    Bid (Size) 67.81 (100)
    Ask (Size) 67.95 (200)
    Prev. Close 67.12
    Today's Range 67.09 - 69.32
    52wk Range 51.06 - 82.22
    Shares Outstanding 142,334,900
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
    Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the exp... 
    Via StockStory
    Topics Earnings
    News headline image
    Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
    What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi... 
    Via StockStory
    Topics Economy

    Performance

    YTD
    -3.5%
    -3.5%
    1 Month
    -2.0%
    -2.0%
    3 Month
    -15.7%
    -15.7%
    6 Month
    -3.8%
    -3.8%
    1 Year
    +27.4%
    +27.4%

    More News

    Read More
    News headline image
    Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
    Via StockStory
    Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO) Reports Mixed Q4 2025 Results with Revenue Beat and Unexpected Loss ↗
    Via Chartmill
    News headline image
    Halozyme (HALO) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Halozyme Therapeutics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
    Via StockStory
    HALOZYME THERAPEUTICS INC (NASDAQ:HALO): A GARP Stock with Strong Growth and Reasonable Valuation ↗
    Via Chartmill
    Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth and Technical Setup ↗
    Via Chartmill
    News headline image
    Halozyme Therapeutics Earnings: What To Look For From HALO
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
    Via StockStory
    News headline image
    3 Cash-Producing Stocks with Exciting Potential
    Via StockStory
    News headline image
    2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
    Via StockStory
    News headline image
    1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
    Via StockStory
    News headline image
    Unpacking Q4 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    2 Reasons to Like HALO (and 1 Not So Much)
    Via StockStory
    Topics Stocks
    News headline image
    Halozyme (HALO) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales
    Via StockStory
    News headline image
    Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
    Via StockStory
    Topics Economy
    News headline image
    3 Small-Cap Stocks with Solid Fundamentals
    Via StockStory
    Topics Government
    News headline image
    3 Growth Stocks Set to Flourish
    Via StockStory
    News headline image
    A Look Back at Therapeutics Stocks’ Q3 Earnings: United Therapeutics (NASDAQ:UTHR) Vs The Rest Of The Pack
    Via StockStory
    Topics Artificial Intelligence

    Frequently Asked Questions

    Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
    Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
    The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
    What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
    The current price of Halozyme Therapeutics, Inc. - Common Stock is 67.88
    When was Halozyme Therapeutics, Inc. - Common Stock last traded?
    The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 05/18/26 10:50 AM ET
    What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
    The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 9.66B
    How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
    Halozyme Therapeutics, Inc. - Common Stock has 10B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.